health-managed-care theme · 5 dossiers

Healthcare-staffing cyclical recovery, breaking out: AMN +101% YTD to 52-wk highs ~$32 as temp-nurse demand inflects (Jefferies +3.6% w/w; CCRN travel/allied +7% q/q) and EBITDA recovers. But price sits ~25% above the $25 avg analyst PT on…

Pinned cash merger-arb, not a momentum trade. Knox Lane (PE, no staffing overlap) is taking CCRN private at $13.25 cash; stock $13.18 (Jun 5 close) = ~0.5% gross spread. HSR waiting period lapses 2026-06-22 absent a second request. Upside…

Managed-care margin recovery off the 2025 ACA blowup: +137% to ~$59, now above the ~$55 consensus PT as sell-side upgrades (DB $80, BofA $74) arrive late confirmation, not a fresh leg. Q1 crushed ($3.37 vs $2.13) yet FY guide only >$3.40…

GLP-1-fear-reversal + census-recovery re-rate (+70% YTD) is already paid out: spot ~$192 sits below the $193.71 avg PT, ~5% off the ATH, tape flat 3 weeks, Berkshire trimming, no catalyst until the ~early-Aug Q2 print. MATURING toward…

Value-based oncology turnaround inflecting to first-ever profitability: Q1'26 revenue +41% YoY, Florida capitation now profitable, FY26 adj-EBITDA guide $0–9M. Tripled off $2.02; a 10% owner keeps buying (12k sh @ $4.75, Jun 5). Real,…